Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07790861

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sichuan Provincial People's Hospital, Chengdu, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and <30 kg/m2 or ≥24.0 kg/m2 and <28 kg/m2, and at least 1 of the following weight-related comorbidities at screening:
  • hypertension
  • dyslipidemia
  • obstructive sleep apnea
  • Fatty liver
  • cardiovascular disease
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

  • Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
  • Have a self-reported change in body weight >5 kg within 90 days prior to screening
  • Had chronic or acute pancreatitis any time prior to screening
  • Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome

Treatment and study plan

Orforglipron

Drug

Administered orally.

Other names: LY3502970

Placebo

Drug

Administered orally.

Primary outcomes

  1. Mean Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Mean Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 48

  2. Mean Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 48

  3. Mean Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 48

  4. Mean Change from Baseline in Fasting Glucose

    Time frame: Baseline, Week 48

  5. Mean Percent Change from Baseline in Fasting Insulin

    Time frame: Baseline, Week 48

  6. Mean Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 48

  7. Mean Change from Baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, Week 48

  8. Mean Percent Change from Baseline in Fasting non-HDL Cholesterol

    Time frame: Baseline, Week 48

  9. Mean Percent Change from Baseline in Fasting Triglycerides

    Time frame: Baseline, Week 48

  10. Mean Change from Baseline in Short Form Version 2 (SF-36v2) Acute Form Domain Scores

    Time frame: Baseline, Week 48

Study contacts

Contact information is provided by the study sponsor or research team.

Physicians interested in becoming principal investigators please contact

CONTACT

[email protected]

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

[email protected]

1-317-615-4559

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Acronym: ATTAIN-CN

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 27, 2026
Registry last updated
Aug 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.